GSK and Novartis admit misleading arthritis marketing

May 20, 2019 10:07

Global health giants GlaxoSmithKline and Novartis have admitted in the Federal Court to misleading claims in its marketing of arthritis gels.

The court action, bought by the ACCC in December 2017, alleged the two drug companies made “false or misleading representations” in the marketing of its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.

Subscribe to keep reading

Join Mumbrella Pro to access the Mumbrella archive and read our premium analysis of everything under the media and marketing umbrella.

Paul Wallbank

Paul Wallbank was news editor at Mumbrella between June 2017 and June 2019. Previously he's covered business and technology issues for outlets ranging from The Australian and Sydney Morning Herald to the ABC and Business Spectator.

Topics